To include your compound in the COVID-19 Resource Center, submit it here.

Tariquidar: QLTI started 2 double-blind North American and European Phase III trials of tariquidar as an adjunctive treatment in combination with first-line che

QLT Inc. (QLTI; TSE:QLT), Vancouver, B.C.
Product: Tariquidar (XR9576)
Business: Cancer
Therapeutic category: Adjunct
Target:

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE